key: cord-0694007-117346w8
authors: Steenhuis, M.; van Mierlo, G.; Derksen, N. I. L.; Ooijevaar-de Heer, P.; Kruithof, S.; Loeff, F. L.; Berkhout, L. C.; Linty, F.; Reusken, C.; Reimerink, J.; Hogema, B.; Zaaijer, H.; van de Watering, L.; Swaneveld, F.; van Gils, M. J.; Bosch, B. J.; van Ham, M.; ten Brinke, A.; Vidarsson, G.; van der Schoot, E. C.; Rispens, T.
title: Dynamics of antibodies to SARS-CoV-2 in convalescent plasma donors
date: 2021-01-06
journal: nan
DOI: 10.1101/2021.01.06.20249035
sha: 21e4e09e0b6314ebbe07e8706197bb9daae72f58
doc_id: 694007
cord_uid: 117346w8

The novel SARS-CoV-2 virus emerged in late 2019 and has caused a global health and economic crisis. The characterization of the human antibody response to SARS-CoV-2 infection is vital for serosurveillance purposes as well for treatment options such as transfusion with convalescent plasma or immunoglobin products derived from convalescent plasma. In this study, we measured antibody responses in 844 longitudinal samples from 151 RT-PCR positive SARS-CoV-2 convalescent adults during the first 34 weeks after onset of symptoms. All donors were seropositive at the first sampling moment and only one donor seroreverted during follow-up analysis. Anti-RBD IgG and anti-nucleocapsid IgG levels slowly declined with median half-lifes of 62 and 59 days during 2-5 months after symptom onset, respectively. The rate of decline of antibody levels diminished during extended follow-up. In addition, the magnitude of the IgG response correlated with neutralization capacity measured in a classic plaque reduction assay as well in our in-house developed competition assay. The result of this study gives valuable insight into the longitudinal response of antibodies to SARS-CoV-2.

The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative 53 agent of the on-going coronavirus disease pandemic emerged in Wuhan (China) in December 54 2019. SARS-CoV-2 is classified under the Betacoronavirus 2B and is closely related to SARS-CoV (>80% 55 genomic similarity) and MERS-CoV (50% genomic similarity), which are known of previous outbreaks [1, 56 2] . COVID-19 is a disease that is associated with a wide spectrum of disease severity, ranging from 57 asymptomatic to acute respiratory distress syndrome and is already responsible for more than 1 million 58 deaths worldwide [3] . 59

Besides vaccination, prevention of infection with SARS-CoV-2 might be achieved by transfusion with 60 COVID-19 convalescent plasma (CCP), plasma collected from individuals after recovery from 61 or immunoglobulin products derived from CCP [4] [5] [6] . This therapy would be especially relevant for 62 immunocompromised individuals. Although it has been shown that CCP therapy is safe [7] and it has been 63 approved by the FDA for treatment, the clinical effect especially in severely ill patients seems to be limited 64 [8] . The most potent CCP units are in theory those containing the highest amounts of neutralizing 65 antibodies against SARS-CoV-2. To select convalescent plasma donors with high neutralizing antibody 66 titers it is important to understand the dynamics of antibodies against SARS-CoV-2 in the period after 67 recovery from SARS- Virtually all PCR-confirmed patients develop IgM, IgA and IgG antibodies against the virally encoded 69 surface glycoproteins spike (S) and nucleocapsid protein (NP) [9] [10] [11] . The S protein mediates binding of 70 the virus particle to angiotension converting enzyme-2 (ACE2) on target cells through its receptor binding 71 domain (RBD) [12, 13] , enabling merging of viral and target cell membrane. While a large fraction of anti-72 S antibodies are directed against RBD, of which many are neutralizing [14, 15] , anti-S antibodies binding 73 outside of the RBD may also contribute to neutralization [14, 15] . In addition, antibody levels seem to 74 vary depending on the infection duration and severity of disease, and anti-S and anti-NP antibodies 75 correlate well [16] . 76

Seroprevalence studies have demonstrated that antibodies to SARS-CoV-2 can be detected up to at least 77 3-8 months after disease recovery [17] [18] [19] [20] . However, seroprevalence depends on the characteristics of 78 the study population, on the detection methods used and do not report on the quantitative aspects of 79 the antibody response. Many short-term studies consistently show a seroconversion of IgG, IgA and IgM 80 antibodies against the viral proteins S and NP within 1-3 weeks after symptom onset, depending on 81 disease severity [9] [10] [11] 21] . Less information is available about the long-term course of antibody titers. 82

Several studies investigated the longitudinal antibody response and found that 1 month after onset of 83 symptoms antibody levels reach a plateau followed by rapidly declining IgM and IgA titers, whereas IgG 84 titers seems to remain high up to 6 months [18, 19, [22] [23] [24] [25] [26] . A recent study by Dan et al., in which patients 85 were followed up to 8 months, consistently showed only a modest decline in anti-S IgG titers as well as 86 neutralizing antibody titers [20] . Limitations of these studies include a sometimes limited cohort size, and 87

in particular the number of longitudinal data points available for each subject, which restricts the 88 possibilities to analyze trends in antibody levels over time. 89 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 6, 2021. previously [27] , and who provided written informed consent as part of routine donor selection and blood 107 collection procedures, that were approved by the Ethics Advisory Council of Sanquin Blood Supply 108

Foundation. This study has been conducted in accordance with the ethical principles set out in the 109 declaration of Helsinki and all participants provided written informed consent. 110

Total and isotype-specific antibody ELISA 111 Total antibody, IgM and IgA to RBD was measured as described previously [9] . IgG to RBD and NP were 112 measured essentially as described before [9] , but with several modifications. RBD and NP proteins were 113 produced as described in Vogelzang et al., [9] . IgG1 and IgG3 subclasses were detected by adding 0.5 114 µg/mL HRP-conjugated monoclonal mouse antihuman IgG1 (MH161.1, Sanquin) or 1.0 µg/mL antihuman 115 IgG3 (MH163.1, Sanquin) diluted in PBS supplemented with 0.02% polysorbate-20 and 0.3% gelatin) (PTG) 116 for 30 minutes. Samples were tested 1:1200 diluted for IgG and IgG1 to RBD, and 1:100 diluted for IgG3 117 to RBD. A cut-off was based on the 98 percentile of signals of 240 pre-outbreak plasma samples. Signals 118 were quantified using a serially diluted calibrator consisting of pooled convalescent plasma that was 119 included on each plate. This calibrator was arbitrarily assigned a value of 100 AU/mL. For anti-RBD IgG1 120 and IgG3, the calibrator consisted of recombinantly expressed IgG1 and IgG3 monoclonal antibody. Both 121 antibodies had the same variable regions (clone 1-18), but were engineered with different heavy chains 122 [15, 28] . Results were expressed as arbitrary units per mL (AU/mL) and represent a semi-quantitative 123 measure of the concentrations of IgG antibodies. 124 125 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 6, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Competition ELISA 126 Neutralizing capacity of SARS-CoV-2 antibodies was assessed using a competition assay. Serum samples 127 were incubated 125-fold diluted for 60 minutes with 5 ng/mL biotinylated RBD in PTG. Next, 100 uL 128 aliquots were transferred to MaxiSORP microtiter plates (ThermoFisherScientific, USA) coated with 300 129 ng/mL ACE2 and incubated for 60 minutes. The ACE2 was produced in HEK cells with a HAVT20 leader 130 peptide, 10xhis-tag and a BirA-tag as described by Dekkers et al., [28] . After washing 5 times with PBS 131 supplemented with 0.02% polysorbate-20 (PBS-T), plates were incubated for 30 minutes with 132 streptavidin-poly-HRP (M2032, Sanquin). Plates were washed five times with PBS-T, and 100 μL of TMB 133 substrate (100 μg/mL) and 0.003% (v/v) hydrogen peroxide (Merck, Germany) in 0.11 M sodium acetate 134 buffer (pH 5.5) was added to each well. A total of 100 μL of 0.2 M H 2 SO 4 (Merck, Germany) was added to 135 stop the reaction. Absorbance was measured at 450 nm and 540 nm. The difference was used to evaluate 136 RBD binding. As such, results were corrected for background signals (absence of RBD) and expressed as 137 percentage binding relative to the uninhibited condition (% non-inhibited signal). 138

Neutralization assay 139 Sera were tested by a SARS-CoV-2-specific virus neutralization test (VNT) based on a protocol described 140 previously with some modifications [29] . In brief, replicate serial dilutions of heat-inactivated samples (30 141 minutes at 56°C) were incubated with 100-fold tissue culture 50% infectious dose of SARS-CoV-2 for 1 142 hour at 35°C. African green monkey (Vero-E6) cells were added in a concentration of 2 × 10 4 cells per well 143 and incubated for 3 days at 35°C in an incubator with 5% carbon dioxide. The 50% virus neutralization 144 titer (VNT50), defined as the highest serum dilution that protected more than 50% of cells from 145 cytopathological (lysed cells) effect, was taken as the neutralization titer. Samples with titers ≥10 were 146 defined as SARS-CoV-2 seropositive. 147

Data processing and analysis 148 Initial evaluation of IgG levels resulted in identification of 20 samples for which we observed either a >4-149 fold drop in level/wk or 4-fold difference/2 wk with consecutive follow-up before and after. These were 150 excluded from all further analyses. 151

For the remaining 676 samples collected between March 30 and August 14, the longitudinal changes in 152

IgG antibody levels were analyzed by linear mixed effects modeling in R (v3.6.0) using the LmerTest 153 package (v3.1.2). We assumed first-order decay in concentrations, and therefore a linear trend in the log-154 transformed concentrations with time. Time was used as fixed variable, with random intercept for subject 155 and random slope for time to account for individual clearance rates. 156

Statistical analysis were carried out using Graphpad Prism 7. Subgroup analysis on individual baseline

A total of 151 adult CCP donors were selected who were tested RT-PCR positive (nasopharyngeal swab) 163 for SARS-CoV-2 (baseline information can be found in Table 1 ). On average, the first donation was 164 collected 59 days after onset of COVID-19 symptoms. Additional plasma samples per donor were 165 sequentially collected for up to 34 weeks after onset of symptoms, resulting in 844 plasma samples in 166 total. Of these, 20 samples were excluded as outliers (details see M&M), resulting in 676 samples for 167 period 1 (up to 22 weeks after symptom onset; last sample median 110 days after symptom onset) and 168 another 148 samples for period 2 (extending to 34 weeks after symptom onset). During period 2, many 169 donors were no longer donating due to insufficient titers, and this extended range is thus only available 170 for a biased selection of plasma donors (n=55). Initial analysis of the antibody response to SARS-CoV-2 171 was therefore focused on period 1. 172

To study seroprevalence to SARS-CoV-2 we used our recently described sensitive total antibody bridging 174 assay (so called RBD-Ab) to RBD [9]. All donors were positive for SARS-CoV-2 antibodies as assessed with 175 the RBD-Ab assay, except for two samples, which belong to one donor that seroreverted at week 13 after 176 tested positive at week 10 ( Figure 1A ). In addition, using isotype-specific assays [9] we determined 177 seroprevalence of IgA, IgG and IgM to RBD. All samples collected before week 5 were seropositive for IgG 178 against RBD ( Figure 1A ). As time progressed only a small fraction of samples fell below the detection limit 179

for IgG, indicative that IgG levels remain in circulation for substantial periods after recovery, consistent 180 with other studies [18, 19] . In contrast, the amount of samples that were seropositive in the IgA and IgM 181 isotype specific assay were 75% and 68.8% before week 5, respectively, and gradually declined during the 182 study period, in line with previous studies [18, 19] . 183

184 To obtain better insight into the antibody response we quantitatively analyzed the SARS-CoV-2 IgG 185 antibodies against NP and RBD in all 151 adult donors. For (relative) quantification, we made use of 186 pooled plasma of CCP donors as calibrator. Antibody concentrations varied >100-fold between individuals 187 for both anti-RBD and anti-NP, in line with a recent study by Dan et al., [20] and were significantly 188 correlated ( Figure 1B ). In addition, consistent with other studies high concentrations were significantly 189 associated with hospitalization (Table 1 ) [30, 31] . Levels were also significantly higher in males than 190 females. However, this is largely due to more men being hospitalized (22 vs 0%); and no significant 191 difference was observed between non-hospitalized males and females (22 vs 17 AU/ml, and 22 vs 16 192 AU/ml, for anti-RBD and anti-NP, resp.; p = 0.28, and 0.14). 193

We also measured the IgG1 and IgG3 subclass responses to RBD at first donation in subclass-specific ELISA 194 assays. To properly allow quantitative comparison, we recombinantly expressed IgG1 and IgG3 195 monoclonal antibodies [15] , which were used as a calibrator. We observed that IgG anti-RBD consisted 196 mainly of IgG1, median for IgG3 is 2.5% (IQR 1.5 -5.1%; Figure S2A ). Since higher subclass ratios were 197 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 6, 2021. ; https://doi.org/10.1101/2021.01.06.20249035 doi: medRxiv preprint reported for antibodies against the S2 vs S1 domain of the S protein [32, 33] , we also tested IgG1 and 198 IgG3 in a subset of samples against the full S protein, but we obtained very similar results ( Figure S2B ). 199

Since titrations of the recombinant antibodies were parallel to the plasma pool used as calibrator ( Table  209 1). There is a very weak correlation between estimated half-life for anti-RBD IgG and anti-NP IgG levels, 210 as shown in Figure 2C (Spearman r = 0.23, p = 0.0037). However, the subset of individuals demonstrating 211 the most rapid decline do so for both types of antibodies. There is a significant but weak negative 212 correlation between half-life and absolute levels ( Figure S1 ), indicating a more rapid decline in individuals 213 with the highest antibody levels. 214

Although IgG3 has a shorter half life than IgG1, we did not observe an association between IgG clearance 215 rate and IgG1 and IgG3 levels in the first sample ( Figure S2C For a subset of 55 donors extended follow-up was available for up to 34 weeks (period 2). Of note, as 220 explained in the M&M, there is a selection bias in this group towards higher antibody levels for period 2. 221

Overall, the declining trends in antibody levels continued ( Figure 3A ,B). Interestingly, the rate of decline 222 appears to decrease at later time points, especially for donors with an initially high decline ( Figure S3 ). 223

The effect is more pronounced for anti-RBD ( Figure 3C ) than anti-NP ( Figure 3D ). 224

To obtain insight into the neutralizing capacity of the antibody response in this population, we carried 226 out a competition ELISA in which binding of RBD to ACE2, the receptor on SARS-CoV-2 target cells, is 227 inhibited by blocking antibodies from plasma samples ( Figure S4 ). We observed a high and significant 228 correlation between anti-RBD IgG levels and the amount of competition ( Figure 4A ), independent of the 229 timing of plasma collection ( Figure 4B ). On the other hand, correlation between anti-RBD IgM or IgA and 230 competition was very weak ( Figure S5 ). This indicates that IgG probably plays an important role in 231 neutralizing SARS-CoV-2 virus particles, especially at the long term. Furthermore, we tested virus 232 neutralization of a subset of the plasma samples (n = 147) using the well-established classic plaque 233 reduction assay using live SARS-CoV-2 virus. We observed a good correlation between plaque reduction, 234 expressed as the titer that reduced plaque formation by 50% (VNT50), with anti-RBD IgG ( Figure 4C ) as 235 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 6, 2021. ; https://doi.org/10.1101/2021.01.06.20249035 doi: medRxiv preprint well with viral neutralization ( Figure 4D ) in the in-house competition assay. This data also indicates that 236 our ELISA-based competition assay could be used to evaluate the virus neutralizing capacity of anti-SARS-237

CoV-2 antibodies in plasma samples. 238

Here we describe the individual dynamics of the longitudinal antibody response in plasma samples from 240 CCP donors that were followed for up to 34 weeks post onset of COVID-19 disease symptoms. IgG levels 241 against RBD and NP decreased only gradually, albeit with substantial interindividual variation, and the 242 decrease appeared to slow down as time progressed. This information is relevant not only in the context 243 of the persistence of detectable antibody responses over time and the assessment of seroprevalence and 244 immunity in populations, but may also be used to improve the selection procedure of CCP donors for 245 therapies with convalescent plasma. Long-term maintenance of antibody production is provided by a pool of long-lived plasma cells and 258 memory B-cells that can last a lifetime [35] . Several time scales may be identified, of which the longest-259 lasting can have half-lifes in the order of many years, and thus beyond scope of the current study [36] . It 260 will be interesting to continue following the decline of anti-RBD IgG in time and investigate whether the 261 longevity of the antibody response is similar to other coronaviruses, such as SARS-CoV that can still be 262 detected in most individuals 3-years after recovery [37] . The antibody titer required for protection against 263 re-infection in humans is not yet known, and has to be evaluated also in the context of a recall response 264 upon re-infection. Recent studies provide evidence that upon infection, individuals develop SARS-CoV-2 265 specific memory B and memory T cells that can be detected for up to 240 days, with numbers of IgG 266 memory B cells increasing over time and plateauing after ca. 150 days [20, 38] . The relationship between 267 long-lasting antibody production and the T and B cell memory compartments requires more investigation. 268

We also quantitatively examined the IgG1 and IgG3 subclass response and found that in our study 269 population IgG1 appeared to be by far the dominant IgG subtype. This is in contrast to previous studies 270 that suggest an IgG subclass ratio skewed towards IgG3 during SARS-CoV-2 infection [33, 39] . A possible 271 explanation for this discrepancy is that in these studies the plasma samples were collected shortly after 272 COVID-19 disease recovery, while in our study samples were collected up to 22 weeks after onset of 273 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 6, 2021. ; https://doi.org/10.1101/2021.01.06.20249035 doi: medRxiv preprint disease symptoms. A strength of the current study is the use of matching IgG1 and IgG3 monoclonal anti-274 S antibodies that allowed reliable quantification of the relative amounts of IgG1 and IgG3. 275

The dynamics of the SARS-CoV-2 antibodies play an important role in CCP donor recruitment in order to 276 select the most optimal timing of plasma collection, in which the level of IgG probably plays a crucial role. 277

Potent CCP units should in theory contain high amounts of neutralizing antibodies against SARS-CoV-2. 278

We observed a good correlation between anti-RBD IgG and both a classic plaque reduction viral 279 neutralization assay, consistent with previous studies [40, 41] , as well as a straightforward competition 280 ELISA that indirectly assesses viral neutralization by measuring the ability of plasma containing anti-SARS-281

CoV-2 antibodies to prevent interaction between RBD and ACE2. This suggests that a competition assay 282 may also reliably report on viral neutralization. Of note, a recent study by Gasser et al., found that 283 depletion of IgM resulted in a substantial loss of virus neutralization of the corresponding plasma 284 samples, suggesting a role of IgM in virus neutralization [42] . However, IgM (and IgA) levels will drop 285 relatively fast after recovery. Indeed, many plasma donations did not contain detectable amounts of IgM 286 or IgA. Accordingly, we observed only a very weak correlation between viral neutralization in the 287 competition assay and IgM levels. 288

In line with other studies, higher IgG levels were found for patients that were hospitalized than those 289 with milder symptoms not requiring hospitalization, indicating that severely ill patients are more suitable 290 for CCP donation [21] . Nevertheless, there are potential caveats for these donors. First, a recent study by 291

Larsen et al., showed that severely ill COVID-19 patients with acute respiratory distress syndrome may 292 display a so-called "afucosylated IgG anti-S response" [43, 44] . In addition, multiple studies reported the 293 presence of autoantibodies against a.o. type I IFN-α2 and IFN-ω in patients with severe COVID-19 294 pneumonia that also show high IgG titers [45] [46] [47] [48] [49] . These parameters might negatively impact the outcome 295 of therapies with convalescent plasma, and suggest that it may be safer to rely on convalescent plasmas 296 from patients with mild symptoms, despite the fact that those tend to have lower antibody-response. In 297 conclusion, this study provides insight into the individual dynamics of antibody levels to SARS-CoV-2 298 during up to 34 weeks after symptom onset. Substantial (several-fold) variation in individual half-lifes was 299 observed, with median half-lifes of around 60 days for both anti-RBD and anti-NP IgG, and a tendency 300 towards slower rates of decline of antibody levels as time progressed. 301

We would like to thank all the donors who have kindly donated plasma. 303 perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 6, 2021. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 6, 2021. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 6, 2021. 2020. medRxiv. 418 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 6, 2021. ; https://doi.org/10.1101/2021.01.06.20249035 doi: medRxiv preprint preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 6, 2021. perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted January 6, 2021. perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted January 6, 2021. perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted January 6, 2021. perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted January 6, 2021. All rights reserved. No reuse allowed without permission.

perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted January 6, 2021. perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted January 6, 2021. perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted January 6, 2021. perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted January 6, 2021. ; https://doi.org/10.1101/2021.01.06.20249035 doi: medRxiv preprint perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted January 6, 2021. ; https://doi.org/10. 1101 /2021 

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications 320 for virus origins and receptor binding. The Lancet

Identification of a novel coronavirus causing severe pneumonia in human: a 322 descriptive study

A Randomized Trial ofConvalescent Plasma for 325 COVID-19-Potentially Hopeful Signals

Convalescent plasma or hyperimmune immunoglobulin for people with COVID-327 19: a living systematic review

Effect of Convalescent Plasma on Mortality among Hospitalized Patients with 329 COVID-19: Initial Three-Month Experience. medRxiv

Early safety indicators of COVID-19 convalescent plasma in 5000 patients

Prevention of severe COVID-19 in the elderly by early hightiter plasma

Development of a SARS-CoV-2 Total Antibody Assay and the Dynamics of 335

Antibody Response over Time in Hospitalized and Nonhospitalized Patients with COVID-19

Antibody response to SARS-CoV-2 infection in humans: a systematic review

The Antibody Response to SARS-CoV-2 Infection

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: 342 implication for development of RBD protein as a viral attachment inhibitor and vaccine

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 345 receptor

The receptor binding domain of the viral spike protein is an 347 immunodominant and highly specific target of antibodies in SARS-CoV-2 patients

Potent neutralizing antibodies from COVID-19 patients define 350 multiple targets of vulnerability

Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and 352 recovery from COVID-19

Longitudinal dynamics of the neutralizing antibody response to SARS-CoV-2